Portuguese 
English 
Spanish 
2 min of reading 
0 comments 
Learn More About The Arrival Of The So-Called “Brazilian Ozempic,” A Version Of Liraglutide That Promises To Be Cheaper And More Accessible.
A new and promising option for the treatment of diabetes and obesity has just arrived on the national pharmaceutical market.
The largest pharmaceutical laboratory in Brazil, EMS, under the command of the NC group, announced the arrival of a version of liraglutide that promises to be cheaper and more accessible.
The first liraglutide pens are already in the warehouses of the largest pharmacy chains and will start being sold from next Monday, August 4.
-
The Galaxy A27, Samsung’s new affordable mid-range device, is getting closer to hitting the market after receiving FCC certification in the United States, with a launch expected in the second half of 2026. According to leaks, its specifications include a Snapdragon chip and a 50 MP camera.
-
Larger than any rocket ever launched, the Sea Dragon was designed to emerge from the ocean like a burning skyscraper, standing 150 meters tall, 23 meters in diameter, and weighing over 15,000 tons: Aerojet’s monster would place 550 tons into low orbit and seemed too big even for NASA’s plans.
-
Presented as the world’s first floating megacity, the Freedom Ship promises to be 1.6 km long, 30 stories high, and powered by nuclear energy to accommodate up to 80,000 people at sea, in a project valued at around 81 billion reais that still depends on financing.
-
More durable tires may result from an MIT discovery that makes plastic break the right way, absorb impacts at 750 meters per second, and reduce wear related to microplastics.
Liraglutide And EMS’s Big Bet
Liraglutide, the active ingredient in EMS’s new medications, is a molecule from the class of GLP-1 analogs, which has proven effective in glycemic and weight control.
The public is already familiar with this substance, as it is the same active ingredient in Saxenda, one of Novo Nordisk’s most popular medications, as well as semaglutide present in Ozempic.
EMS’s initiative is a milestone for the national pharmaceutical industry, representing a strategic investment of over R$ 1 billion to enable the production of the pens.
This investment culminated in the inauguration of a modern peptide factory in the country in 2024, in Hortolândia (SP), ensuring that the entire process is conducted on national soil.
Availability And Affordable Prices
Starting next week, the medications Olire, for the treatment of obesity, and Lirux, for the control of type 2 diabetes, will be available at Raia, Drogasil, Drogaria São Paulo and Pacheco chains, bringing new options to millions of Brazilians.
Initially, a total of 100 thousand Olire pens and 50 thousand Lirux pens were distributed.
The main advantage for the consumer, besides national production, is the more affordable prices.
The medications will have suggested prices starting at R$ 307.26 (pack of 1 pen), R$ 507.07 (Lirux with 2 pens) and R$ 760.61 (Olire with 3 pens).
The estimate is that these prices represent a significant savings compared to imported products, making treatment more viable in the long term.
Growth Projection And Market Impact
The pharmaceutical company stated that the initial distribution is just the beginning.
The expectation is that, by the end of this year, 250 thousand units should be available in retail, with a progressive increase in production capacity.
The goal is to reach the mark of 500 thousand pens by August 2026, solidifying the presence of the medications in the market and meeting the growing demand for effective treatments for obesity and diabetes.
EMS’s initiative not only strengthens the national industry but also promises to democratize access to essential therapies for the health of the population.
Que bom, muitas pessoas realmente precisam, um medicamento desse não pode ser previliegio de poucos pela ganancia de uma minoria.